Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 18.02.2019 1 Am J Respir Crit Care Med 1 Ann Oncol 4 Ann Surg Oncol 5 BMC Cancer 2 Br J Cancer 1 Cancer Cell 2 Cancer Chemother Pharmacol 1 Cancer Res 2 Cancer Sci 1 Clin Cancer Res 1 Clin Exp Metastasis 1 Clin Lung Cancer 1 Epidemiology 1 Eur J Cancer 2 Eur Respir J 1 Int J Cancer 1 J Cancer Res Clin Oncol 2 J Comput Assist Tomogr 2 J Thorac Cardiovasc Surg 5 J Thorac Oncol 2 Lancet Oncol 1 Lung Cancer 2 Oncol Rep 1 Oncologist 3 PLoS One 1 Science 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Respir Crit Care Med

1. CHRISTENSON S, Hersh CP
   Found in Translation: Multi-omics Assessment of the COPD-Lung Cancer Interaction.
   Am J Respir Crit Care Med. 2019 Feb 12. doi: 10.1164/rccm.201901-0156.
   PubMed     Text format    
   
   

   
   Ann Oncol

2. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
   Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer.
   Ann Oncol. 2019 Feb 11. pii: 5315508. doi: 10.1093.
   PubMed     Text format    
   
   

   
   Ann Surg Oncol

3. SAFFARZADEH AG, Blasberg JD
   Beyond TNM: Searching for New Patient-Centric Prognostic Indicators in NSCLC.
   Ann Surg Oncol. 2018;25:3425-3426.
   PubMed     Text format    
   
   
4. AMIT M, Tam S, Abdelmeguid AS, Kupferman ME, et al
   Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma.
   Ann Surg Oncol. 2018 Apr 6. pii: 10.1245/s10434-018-6465.
   PubMed     Text format     Abstract available
   
   
5. OKAMOTO T, Takada K, Sato S, Toyokawa G, et al
   Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung.
   Ann Surg Oncol. 2018;25:1564-1571.
   PubMed     Text format     Abstract available
   
   
6. TOYOSHIMA Y, Hara T, Matsui Y, Nagumo Y, et al
   Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor.
   Ann Surg Oncol. 2018;25:3668-3675.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

7. ZHENG LP, Chen LY, Liao XY, Xu ZH, et al
   Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
   BMC Cancer. 2018;18:1070.
   PubMed     Text format     Abstract available
   
   
8. PU X, Wu L, Su D, Mao W, et al
   Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
   BMC Cancer. 2018;18:1082.
   PubMed     Text format     Abstract available
   
   
9. SHINOZAKI T, Iwami E, Ikemura S, Matsuzaki T, et al
   A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
   BMC Cancer. 2018;18:620.
   PubMed     Text format     Abstract available
   
   
10. D'ALMEIDA O, Mothar O, Bondzie EA, Lieumo Y, et al
    Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
    BMC Cancer. 2019;19:136.
    PubMed     Text format     Abstract available
    
    
11. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

12. WU SR, Lin CH, Shih HP, Ko CJ, et al
    HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0400.
    PubMed     Text format     Abstract available
    
    
13. KIM SH, Go SI, Song DH, Park SW, et al
    Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0398.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Cell

14. HELLMANN MD, Callahan MK, Awad MM, Calvo E, et al
    Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
    Cancer Cell. 2019;35:329.
    PubMed     Text format    
    
    

    
    Cancer Chemother Pharmacol

15. YAMAGUCHI O, Kaira K, Mouri A, Shiono A, et al
    Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Cancer Chemother Pharmacol. 2019 Feb 13. pii: 10.1007/s00280-019-03790.
    PubMed     Text format     Abstract available
    
    
16. KAWATA T, Higashimori M, Itoh Y, Tomkinson H, et al
    Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Feb 14. pii: 10.1007/s00280-019-03788.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

17. FUKUDA K, Takeuchi S, Arai S, Katayama R, et al
    Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.
    Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-2052.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

18. SUKHBAATAR A, Mori S, Saiki Y, Takahashi T, et al
    Lymph node resection induces the activation of tumor cells in the lungs.
    Cancer Sci. 2019;110:509-518.
    PubMed     Text format     Abstract available
    
    
19. YONEDA K, Kuwata T, Chikaishi Y, Mori M, et al
    Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:726-733.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

20. TREFNY MP, Rothschild SI, Uhlenbrock F, Rieder D, et al
    A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-3041.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

21. YOUNG ED, Strom K, Tsue AF, Usset JL, et al
    Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1.
    Clin Exp Metastasis. 2018;35.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

22. TOMASINI P, Mascaux C, Jao K, Labbe C, et al
    Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30333.
    PubMed     Text format     Abstract available
    
    

    
    Epidemiology

23. MARGULIS AV, Fortuny J, Kaye JA, Calingaert B, et al
    Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom.
    Epidemiology. 2018;29:e41-e42.
    PubMed     Text format    
    
    

    
    Eur J Cancer

24. WANG Z, Huang C, Yang JJ, Song Y, et al
    A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
    Eur J Cancer. 2019;109:183-191.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

25. MASSARD G, Tabin N, Mitchell S, Batirel H, et al
    A harmonised European training syllabus for thoracic surgery: report from the ESTS/ERS task force group.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
26. KURMI OP
    Is low level of vitamin D a marker of poor health, or a cause?
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    

    
    Int J Cancer

27. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

28. PARK HL, Yoo IR, Boo SH, Park SY, et al
    Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
    J Cancer Res Clin Oncol. 2019 Feb 13. pii: 10.1007/s00432-019-02858.
    PubMed     Text format     Abstract available
    
    

    
    J Comput Assist Tomogr

29. YU Y, Wang X, Shi C, Hu S, et al
    Spectral Computed Tomography Imaging in the Differential Diagnosis of Lung Cancer and Inflammatory Myofibroblastic Tumor.
    J Comput Assist Tomogr. 2019 Feb 11. doi: 10.1097/RCT.0000000000000840.
    PubMed     Text format     Abstract available
    
    
30. LI X, Enzerra M, Smith DA, Rahnemai-Azar AA, et al
    Lesser Known Facts of Small Cell Lung Cancer.
    J Comput Assist Tomogr. 2019 Feb 11. doi: 10.1097/RCT.0000000000000847.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Cardiovasc Surg

31. SAMSON P
    It's time to check our bias: Ensuring health equity for patients with lung cancer.
    J Thorac Cardiovasc Surg. 2018 Dec 27. pii: S0022-5223(18)33499.
    PubMed     Text format    
    
    
32. YANG CJ, Yendamuri S, Mayne NR, Battoo A, et al
    The role of thoracoscopic pneumonectomy in the management of non-small cell lung cancer: A multicenter study.
    J Thorac Cardiovasc Surg. 2018 Dec 18. pii: S0022-5223(18)33419.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

33. JEANSON A, Tomasini P, Souquet-Bressand M, Brandone N, et al
    Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040.
    PubMed     Text format     Abstract available
    
    
34. ZIMMERMAN S, Das A, Wang S, Julian R, et al
    2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 11. pii: S1556-0864(19)30099.
    PubMed     Text format     Abstract available
    
    
35. LEE JW, Zhang Y, Eoh KJ, Sharma R, et al
    The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111.
    PubMed     Text format     Abstract available
    
    
36. HSU WH, Zhao X, Zhu J, Kim IK, et al
    Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108.
    PubMed     Text format     Abstract available
    
    
37. AGGARWAL R, Lam AC, McGregor M, Menezes R, et al
    Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

38. BALL D, Mai GT, Vinod S, Babington S, et al
    Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30896.
    PubMed     Text format     Abstract available
    
    
39. ALSHAFA F, Palma D
    CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30953.
    PubMed     Text format    
    
    

    
    Lung Cancer

40. HENDRIKS LEL, Dingemans AC
    Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
    Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297.
    PubMed     Text format    
    
    

    
    Oncol Rep

41. MA HP, Kong WX, Li XY, Li W, et al
    miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR.
    Oncol Rep. 2019 Jan 24. doi: 10.3892/or.2019.6983.
    PubMed     Text format     Abstract available
    
    
42. ZHANG T, Ma L, Wu P, Li W, et al
    Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in nonsmall cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
    Oncol Rep. 2019 Jan 22. doi: 10.3892/or.2019.6976.
    PubMed     Text format     Abstract available
    
    

    
    Oncologist

43. SONBOL MB, Halling KC, Douglas DD, Ross HJ, et al
    A Case of Donor-Transmitted Non-Small Cell Lung Cancer After Liver Transplantation: An Unwelcome Guest.
    Oncologist. 2019 Feb 12. pii: theoncologist.2018-0517.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

44. HSU JC, Lin JY, Hsu MY, Lin PC, et al
    Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    PLoS One. 2018;13:e0202725.
    PubMed     Text format     Abstract available
    
    
45. SONG JH, Kim S, Lee HW, Lee YJ, et al
    Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit.
    PLoS One. 2019;14:e0210951.
    PubMed     Text format     Abstract available
    
    
46. FU JY, Wan YL, Huang TY, Wu CF, et al
    Correction: Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection.
    PLoS One. 2019;14:e0212461.
    PubMed     Text format     Abstract available
    
    

    
    Science

47. RUSCETTI M, Leibold J, Bott MJ, Fennell M, et al
    NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
    Science. 2018;362:1416-1422.
    PubMed     Text format     Abstract available
    
    

    
    Semin Oncol

48. PILOTTO S, Carbognin L, Rossi A, Tortora G, et al
    Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
    Semin Oncol. 2018;45:176-180.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: